Amgen (AMGN) Non-Current Assets (2009 - 2026)
Amgen (AMGN) posted quarterly Non-Current Assets of $61.0 billion for Q1 2026, down 2.26% year-over-year from $62.4 billion in Q1 2025, and down 0.81% quarter-over-quarter from $61.5 billion in Q4 2025.
Amgen (AMGN) Non-Current Assets (2009 - 2026) Analysis & Trends
Amgen's Non-Current Assets history runs 18 years deep, the most recent figure standing at $61.0 billion for Q1 2026.
- In Q1 2026, Non-Current Assets fell 2.26% year-over-year to $61.0 billion; the TTM figure through Mar 2026 stood at $246.0 billion (down 2.8% YoY), while the FY2025 annual figure was $61.5 billion, down 2.04% from the prior year.
- Non-Current Assets for Q1 2026 stood at $61.0 billion, down from $61.5 billion in the prior quarter.
- The five-year high for Non-Current Assets was $66.8 billion in Q4 2023, with the low at $39.6 billion in Q3 2022.
- The 5-year median for Non-Current Assets is $61.2 billion (2025), against an average of $54.3 billion.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets surged 55.64% in 2023, then dropped 6.01% in 2024.
- Amgen's Non-Current Assets stood at $42.9 billion in 2022, then soared by 55.64% to $66.8 billion in 2023, then fell by 6.01% to $62.8 billion in 2024, then declined by 2.04% to $61.5 billion in 2025, then fell by 0.81% to $61.0 billion in 2026.
- Business Quant data shows AMGN's Non-Current Assets at $61.0 billion in Q1 2026, $61.5 billion in Q4 2025, and $62.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 141.29 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 101.45 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 125.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 94.68 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 87.87 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 60.68 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 35.42 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 159.77 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 59.27 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 113.37 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 60.68 Bn |
| Mar 31, 2026 | 61.03 Bn |
| Dec 31, 2025 | 61.53 Bn |
| Sep 30, 2025 | 62.26 Bn |
| Jun 30, 2025 | 61.16 Bn |
| Mar 31, 2025 | 62.44 Bn |
| Dec 31, 2024 | 62.81 Bn |
| Sep 30, 2024 | 64.12 Bn |
| Jun 30, 2024 | 63.70 Bn |
| Mar 31, 2024 | 64.95 Bn |
| Dec 31, 2023 | 66.82 Bn |
| Sep 30, 2023 | 42.06 Bn |
| Jun 30, 2023 | 42.89 Bn |
| Mar 31, 2023 | 44.02 Bn |
| Dec 31, 2022 | 42.94 Bn |
| Sep 30, 2022 | 39.64 Bn |
| Jun 30, 2022 | 39.97 Bn |
| Mar 31, 2022 | 40.68 Bn |
| Dec 31, 2021 | 41.78 Bn |
| Sep 30, 2021 | 40.61 Bn |